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Abstract. Objective: To assess and compare the pharmacokinetics and bioavailability of methyler- 
gometrine (ME) in men and non-pregnant women. Design: A cross-over design was used for an 
oral dose of 0,125 mg and an intravenous dose of 0.200 mg of ME in 6 men and 6 non-pregnant 
women (parallel-design in gender). Results: After intravenous administration, the pharmacokinetic 
profile of ME was described with a 2-compartment model. The distribution half-life (ti/2a) in men 
was 0.19 ±0.27 h, in women 0.10±Q.04h, the elimination half-life (ti/2p) 1.85 ±0.28 h, respectively, 
1.94 ± 0.34 h and the total body clearance (CL) 33.2 ± 11.8 1.1T1, and, respectively, 22.18 ±3.10 
LIT1. For these intrinsic pharmacokinetic parameters differences between men and women were not 
statistically significant. After oral administration, the pharmacokinetic profile was described with 
a 1-compartment model. The lag time was subject dependent and was significantly longer in men 
0.33 ± 0.09 h than in women 0.09 ± 0.07 h, Ti/2p in men was 2.08 ± 0.43 h and was longer than in 
women 1.42 ± 0.31 h (p = 0.012). In both men and women a large variation of bioavailability was 
shown ranging between 22% and 138%, Conclusion: This study with oral methylergometrine 
showed a comparable large interindividual variability in bioavailability in both men and women.
Key words: post partum hemorrhage (PPH) - methylergometrine maleate - HPLC analysis - 
pharmacokinetics - bioavailability
Introduction
Methylergometrine belongs to the group of oxytocic 
drugs enhancing uterine motility. Prophylactic use in the 
third stage of labor of these drugs, such as ergometrine, 
methylergometrine and oxytocin, reduces the risk of post 
partum hemorrhage (PPH) and the need for further oxy­
tocic therapy in the puerperium [Van Dongen et al. 1991]. 
The use of oxy tocics in the post partum period is advocated 
for the prevention and the management of PPH [Prendiville
et al. 1988].
PPH is still one of the mos t common causes of mater­
nal death [Royston and Armstrong 1989]. In such cases 
death invariably occurs within a few hours after childbirth. 
Prevention and management of this condition should take 
place at all levels of obstetric care as emergency referral is
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often difficult to arrange, especially in circumstances pre­
vailing in many third world countries. Drugs in tropical 
climates have to fulfill extra requirements. They have to be 
stable [Hogerzeil et al 1991,1992, Walker et al. 1988], the 
route of administration has to be simple. Also untrained 
people should be able to administer the drug safely. From 
the group of oxytocics, only the ergot alkaloids (ergome­
trine maleate and methylergometrine maleate) can be given 
by mouth.
Because pharmacokinetic data of ergometrine in men 
showed such a great variation in bioavailability, a com­
parable study was performed for methylergometrine in 
both men and (non-pregnant) women to investigate and 
compare the results with the data obtained before [De 
Groot et al. 1994]. A sensitive and selective high perform­
ance liquid chromatographic (HPLC) system with fluores­
cence detection developed for ergometrine was modified 
for the analysis of methylergometrine to enable its pharma­
cokinetic analysis and bioavailability [De Groot et al. 
1993a], The aim of this study was to investigate pharma­
cokinetics and bioavailability of methylergometrine in men 
and women.
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Subjects, material and methods
For the assesment of the biovailability of methylergometrine a 
randomized cross-over design was used for the intravenous and oral 
administration of methylergometrine. The interval between administra­
tion of both was at least 2 weeks.
A single oral dose of methylergometrine maleate 0.125 mg (= 0.95 
mg base) was taken after a standard breakfast containing 2 sandwiches, 
no cheese and unrestricted amounts of coffee or tea by all subjects. 0.200 
mg methylergometrine maleate (= 0.152 mg base) was injected intraven­
ously in the same volunteer after a similar standard breakfast.
Intravenous administration: Intravenous injection took place over 
1 minute in the opposite arm where the Venflon was located. In addition 
to the sampling times as described under oral administration, 2 extra 
samples were taken at 3 and 5 minutes after the start of the injection.
After centrifugation of the blood samples at 11,000 g for 5 min, 
plasma samples from both the oral and intravenous groups were stored at 
-20° C pending analysis.
Care was taken that the whole intravenous dose was administrated 
by cleaning the i.v. dosage line with 1 ml 0.9% saline.
Subjects
Six men and 6 women volunteered for the pharmacokinetic study 
of both oral and intravenous administration of methylergometrine. The 
subjects were screened for possible contra-indications (cardiovascular 
disease and chronic obstructive lung disease). Bodyweight/height, blood 
pressure, hemoglobin level, liver and renal functions were recorded. In 
Table 1 the mean ±SD of the demographic data of the volunteers are 
shown. They all had normal liver and renal functions. During the experi­
ments blood pressure was monitored. This study was approved by the 
Committee Experimental Research Involving Human Subjects (CEOM) 
of the Academic Hospital Nijmegen Sint Radboud, the Netherlands.
Drugs
Pure methylergometrine (reference substance 108) was obtained 
from Sandoz Pharma AG (Basel, Switzerland). Methylergometrine ma­
leate 0.125 mg tablet Methergin (equivalent to 0.095 mg free base) was 
obtained from Sandoz Germany (Nürnberg, Germany, batch No 3001).
Methylergometrine maleate 0.20 mg ml (injectable solution) was 
obtained from Sandoz (Uden, The Netherlands, batch No 475 MFD 
920812). These methylergometrine batches fulfilled the requirements of 
a content uniformity test according to standard quality control criteria.
The injectable solution contained 93.3 ± 6.5% of the claimed 
content (n = 20).
Drug analysis
Methylergometrine in plasma was measured using the modified 
HPLC assay with fluorescence detection of de Groot et al [1993a]. In short 
the HPLC analysis is as follows:
Column: 25 cm x 4.6 mm ID packed with Spherisorb 5-ODS 
(particle size 5 ¡nm, Chrompack, Middelburg, the Netherlands) with a 
guard column (75 mm x 2.1 mm ID) packed with 10 |iin pellicular 
reversed phase (Chrompack, catalogue No 028653), An injection loop of 
100 |il was used.
The mobile phase consisted of a mixture of 0.067 M potassium 
dihydrogenphosphate and 0.5 ml of diethyiamine in water (1:1, v/v) as 
solvent A, and acetonitrile as solvent B. The mixture consisted of 60% A 
and 40% B (v/v). All reagents were of analytical grade (Merck, Darmstadt, 
Germany). The flow rate was 1.2 ml.min . Fluorescence detection was 
achieved at 315 nm excitation and 430 nm emission. The retention time 
was 8.61 min, capacity factor was 3.76 and the analysis was carried out 
at room temperature. The quantitation limit of methylergometrine in water 
was 120 pg ml and that in plasma 150 pg ml , both at a signal-to-noise 
ratio of 3. The intra-day variation was 3% and inter-day variation 5%.
Sample treatment
Plasma samples of 300 Jil were deproteinated by acetonitrile 300 
fil, and centrifuged at 11,000 g for 5 minutes. Of the clear supernatant 100 
\i\ were injected onto the column.
Sampling
Oral administration of methylergometrine: Five ml blood samples 
were collected through an intravenous (IV) canula (Venflon 1.0 mm OD) 
in tubes containing 0.5 mg Li heparin at times: 0, 10, 20, 30, 60, 90, 180, 
270, 360, 450 and 540 minutes after administration.
Table 1 Pharmacokinetic parameters (mean ± SD) of methylergome­
trine (0.152 mg i.v) in females and males (n = 6)
Parameter
Females Males P
tl/2oc (h) 0.10 + 0.04 0.19 ±0.27 0.46
tl/2ß (h) 1.94 ±0.34 1.85 ±0.28 0.64
MRT u v. (W 2.31 ±0.31 2.25 ± 0.44 > 0.8
AUCo-~> (ng.h.r1) 6.02 ± 0.63 4.59 ± 1.82 0.10
CL (l.h“1) 22.2 ± 3.10 32.2+11.8 0.073
Vss (1) 50.8 ±8.23 71.5 + 25.9 0.091
Vss kg~‘ (1 -kg”1 ) 0.84 ±0.12 0.96 + 0.36 0.43
Pharmacokinetic analysis
The pharmacokinetic parameters were calculated using a 2-com- 
partment model after intravenous administration and after oral adminis­
tration a 1-compartment model with lag-time of the MW/Pharm computer 
program (Mediware, Groningen, the Netherlands) [Proost and Meyer 
1992]. Cm ax is the maximum plasma concentration read from the fitted 
plasma concentration-time curve (r > 0.98), and tmax the time at which 
Cmax occurs. The ti/2p values were calculated from ln(2)/(3, where [3 is 
calculated by log-linear regression analysis of the terminal log-linear 
phase. The ti/2absorption and ti/2a were obtained by line feathering and 
linear regression analysis.
Mean absorption time (MAT) was used as a measure of the rate of 
absorption and calculated as the difference between (MRTp0-tlag) and 
MRTi.v..
AUCo-oo is the area under the plasma concentration-time curve and 
was calculated using the linear trapezoidal rule with extrapolation of t = 
using Ct/p with Ct being the last measured concentration.
The bioavailability (F) is AUCoral- dosei>vyAUCi.v..doseoral. Total 
body clearance CL = F.dose/AUCo_oo. Vss is the volume of distribution 
in steady state (Vss = F.dose.AUMCo^WAUCo-« ).
Analysis of variance was conducted according to standard proce­
dures. The level of significance was defined at p = 0.05.
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Results
Mean age (years) was 35.7 ± 13 in men and 41.2 ± 5 
in women. The mean weight (kg) was 75 ± 4 in men and 
61 ± 7 in women. The mean height (cm) was 181 ± 8 in 
men and 167 ± 7 in women. The mean blood pressure was 
systolic (mmHg) 119 ± 4,9 and, respectively, 114 ± 10; 
diastolic pressure (mmHg) 78 ± 7.1 and, respectively, 71 ± 
7. Only weight and height were statistically different in 
men and women.
Figure 1 (left panel) shows the methylergometrine 
plasma concentrations (ng ml-1) versus time curves after 
oral administration of 0.125 mg methylergometrine ma- 
leate (= 0.095 mg free base) and after intravenous admin- 
is tr at ion of 0.200 mg methylergometrine male ate (= 0.152 
mg free base) in 1 representative male subject (# 6) and in
1 female subject (# 3, right panel).
In the male the compound was fairly rapidly absorbed 
after oral administration; the lag time is 30 minutes. The 
half-lives after oral and intravenous administration were 
comparable. The relative bioavailability (F) in this subject 
of the oral administration was calculated to be 1.36 (136%).
In the female a maximum plasma concentration of 
1.28 ng.mF1 was reached after 38 minutes and a lagtime of
7 minutes. The relative bioavailability (F) in this subject of 
the oral administration was calculated to be 0.73 (73%).
Table 1 summarizes the pharmacokinetic parameters 
of 0.152 mg methylergomeirine (base) after intravenous 
administration in the 6 men and 6 women. The pharmaco­
kinetic profile can be described with a 2-compartment 
model. No statistically significant difference between men 
and women was observed in intrinsic pharmacokinetic 
parameters ti/2a> ti/2p, total body clearance (CL) and the 
volume of distribution (Vss).
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Table 2 summarizes the pharmacokinetic parameters 
of 1 dose of oral methylergometrine (base) in the same men 
(6) and women (6). The pharmacokinetic profile can be 
described with a 1-compartment model. In men and 
women, the biovailability (F) is subject-dependent and 
ranges between 22.2% and 138.0%, with the assumption 
that the total body clearance is similar after intravenous and 
oral administration. No statistical differences between men 
and women were observed in tm&bs, mean absorption time 
(MAT), CL and Vss kg-1.
Side effects: Three men experienced a "weird" sensa­
tion after intravenous administration. These and other side 
effects were not noted by the other men. Three women 
became dizzy after the methylergometrine injection, after 
oral dosing none of them experienced side effects.
Discussion
The prophylactic use of oxytocic drugs as 
(methyl)ergometrine is generally advocated to prevent 
maternal deaths from post partum hemorrhage (PPH) 
[WHO 1990]. On a world-wide basis, logistic problems are 
encountered when these prophylactic drugs should be ad­
ministered intravenously. Moreover, methylergometrine 
administered i.v. may cause severe hypertensive and car­
diovascular accidents [De Groot et al. 1993b]. The aim of 
this study was to examine whether oral methylergometrine 
could be a possible alternative to injectable oxytocics used 
in the third stage of labor.
We showed unexpected large variations in bioavai- 
libity and pharmacokinetics of oral ergometrine in men [De 
Groot et al. 1994]. In this study we show an identical 
variation in bio availability of methylergometrine in men
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Fig. 1 Left panel (M): 
Methylergometrine plasma con­
centration curves versus time 
curves after administration of an 
intravenous (i.v.) dose of 0.152 
mg methylergometrine base and 
after oral administration (p.o.) 
of 0.095 mg methylergometrine 
base to 1 representative male.
Fig, 1 Right panel (F): 
Methylergometrine plasma con­
centration curves versus time 
after administration of an in­
travenous (i.v.) dose of 0.152 
mg methylergometrine base and 
after oral administration (p.o.) 
of 0.095 mg methylergometrine 
base to 1 representative female.
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and non-pregnant women. After oral administration of the 
drug, absorption is subject dependent.
The half-life of absorption (ti/2abs) is the result of 
absorption and distribution processes. Because it was not 
possible to calculate the "distribution phase” after oral 
administration the 1-compartment model was used for the 
data. Calculated by a 1 -compartment model (ti/2abs) data are 
underestimated as this model neglects the distinct distribu­
tion phase. Therefore we calculated the mean absorption 
time (M AT). M A T  is an alternative method to measure the 
rate of absorption and is model-independent. M A T  can be 
calculated from (M R T po-tiag) -MRTi.v,. For men and 
women the M A T  did not differ significantly. The intrinsic 
pharmacokinetic parameters such as ti/2[i, CL and Vss in 
men and women depend on the drug and not on the route 
of administration (Table 1). The drugs used in the experi­
ments fulfilled the content uniformity test’s requirements. 
Therefore, instability of the used tablets was ruled out as a 
possible explanation of the large interindividual variations 
of bioavailability and lag time, after oral administration.
The intravenous dose was stable and care was taken 
that all of the dose was administered by cleaning the 
syringe with 2 ml of 0.9% saline. The pharmacokinetic
parameters of methylergometrine after intravenous admin­
istration did not show any difference between men and 
women except for the Vss, which was bigger in men (p = 
0.091). This effect was more pronounced after oral admin­
istration of the drug (p = 0 .001).
Oral administration showed more differences be­
tween the pharmacokinetic parameters in men and women. 
Men showed a longer lagtime (p = 0.0004), a greater 
volume of distribution (p = 0 ,001), and a longer ti/2ß (p = 
0.0123). The mean bodyweight of the men was signifi­
cantly larger than that of the women (p = 0.0010). Cor­
rected for the bodyweight, the Vss did not differ for men 
and women after intravenous administration of 0.2 mg 
methylergometrine, respectively, 0.83 ± 0.12 l.kg” 1 for 
men and 0.96 ± 0.36 l.kg-1 for women (p = 0.4). The Vss 
kg" 1 remained larger in men 1.27 ± 0.50 l.kg" 1 than in 
women 0,77 ± 0.05 (l.kg"1, p = 0.0393), after oral admin­
istration of 0.125 mg methylergometrine.
The vast variability of pharmacokinetic parameters 
reported for er go me trine [De Groot et al. 1994] was not 
reported in literature for methylergometrine [Anonymous 
1989, Rail and Schleifer 1985]. It was reported that 
methylergometrine had a fast gastrointestinal absorption,
Table 2 Pharmacokinetic parameters (mean ± SD) of methylergometrine (0.95 mg oral) in females and males (n = 6)
Parameter Females Males P
F (%) 96.4 ±27.5 84,9 ± 37.2 0.56
ting (h) 0.09 ± 0.07 0.33 ±0.09 0.0004
tmax (h) 0.97 + 0.74 0.68 ± 0,22 0,39
Cmax (ng-i]) 1.21 ±0.40 0.77 ± 0.34 0.064
tl/2abs* (h) 0.50 ±0.55 0.08 ± 0.08 0.10
tl/2a (h) — — —
tj/2ß (h) 1.42 ±0.31 2.08 ± 0.43 0.0123
MRTpo (h) 2.87 ±0.56 3.45 ± 0.56 0.10
MAT** (h) 0.57 ± 0.35 0.87 ± 0.72 0.38
AUCo-cx» (M-g.h.l *) 3.49 ± 0.70 2.17 ±0.80 —
CL (ÜT1) 23.6 ±4.01 31.1 ±10.3 0.13
Vss (1) 47.0 ±6.05 94.4 ± 38.9 0.01
Vss kg-1 (l.kg"1) 0.78 ± 0.05 1.26 ±0.50 0.039
- = not detected, * = 1-compartiment model, ** = model independent
Bioavailability (F) AUCorai.doseu./AUCj.v.doseomi
ting (h) lag time
tmax (h) the time at which Cmax occurs
Cmax (M-g.r1) the maximum plasma concentration read from the plasma-concentration-time curve
t|/2abs (h) the half-life of absorption, calculated by least-square linear regression analysis
tj/2a (h) the half-life of distribution, calculated by least-square linear regression analysis
tl/2ß (h) the half-life of elimination, calculated by least-square linear regression analysis
MRTpo (h) the mean residence time AUMC/AUC after oral administration
MRTi.v. (h) the mean residence time AUMC/AUC after intravenous administration
MAT (h)
(jute .h.r1)
a
the mean absorption time (MRTpo-tiag) and MRTi.v.
AUC&-~ the area under the plasma-concentrati on-time curve extrapolated to infinite time
CL d . h ) total body clearance = dose/AUCo-o*
Vss (1) the volume of distribution in steady state (Vss = dose x AUMCo-^/AUCo-«2)
The pharmacokinetic parameters were calculated using the Mediware computer programme (12)
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and that about 60% of the orally administered dose reaches 
the systemic circulation [Mantyla and Kanto 1981, Man­
tyla et al. 1978]. This information was based on only 2 
subjects; more subjects may probably have revealed more 
variation in absorption and other kinetic parameters. We 
found a large variation in bioavailability in methylergome- 
trine for both men and women. In the present study the 
overall bio availability in males was 84.9 ± 37.2%, but the 
variation was 50% (CV), in females these data were, re­
spectively, 96.4 ± 27.5% (28,5% CV).
However, the purpose of administration of oral 
(methyl)ergometrine is to reduce post partum blood loss. 
Therefore, a randomized trial has been set up to show 
whether a clinical effect despite possible varying pharma­
cokinetics can be demonstrated. For the time being, further 
pharmacokinetic research in post partum women is out of 
question, former investigations showed a delayed absorp­
tion compared to absorption in men of oral methylergome- 
trine [Allonen et al. 1978].
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